SC
CGON icon

SummitTX Capital’s CG Oncology CGON Stock Holding History

SummitTX Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,570
Closed -$2.75M – 815
2026
Q1 		$2.75M Sell
40,570
-9,358
-19% -$530K 0.09% 252
2025
Q4 		$2.07M Sell
49,928
-36,690
-42% -$1.52M 0.06% 305
2025
Q3 		$3.49M Buy
86,618
+59,362
+218% +$1.73M 0.14% 163
2025
Q2 		$709K Sell
27,256
-35,935
-57% -$866K 0.03% 437
2025
Q1 		$1.55M Buy
+63,191
New +$1.78M 0.07% 303

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SummitTX Capital's CGON Position: Q2 2026 in Review

SummitTX Capital sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 40,570 shares — an estimated $2.75M sold.

SummitTX Capital first reported a position in CGON in Q1 2025 and held it in 5 quarters. The position peaked at $3.49M in Q3 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • SummitTX Capital reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
  • SummitTX Capital sold 40,570 CG Oncology shares in Q2 2026, an estimated $2.75M.
  • SummitTX Capital first reported a position in CG Oncology in Q1 2025 and held it in 5 quarters.
  • SummitTX Capital's CG Oncology position peaked at $3.49M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.